Tags

Type your tag names separated by a space and hit enter

Mesenchymal stromal cells for acute respiratory distress syndrome (ARDS), sepsis, and COVID-19 infection: optimizing the therapeutic potential.
Expert Rev Respir Med. 2021 03; 15(3):301-324.ER

Abstract

Introduction: Mesenchymal stromal (stem) cell (MSC) therapies are emerging as a promising therapeutic intervention in patients with Acute Respiratory Distress Syndrome (ARDS) and sepsis due to their reparative, immunomodulatory, and antimicrobial properties.Areas covered: This review provides an overview of Mesenchymal stromal cells (MSCs) and their mechanisms of effect in ARDS and sepsis. The preclinical and clinical evidence to support MSC therapy in ARDS and sepsis is discussed. The potential for MSC therapy in COVID-19 ARDS is discussed with insights from respiratory viral models and early clinical reports of MSC therapy in COVID-19. Strategies to optimize the therapeutic potential of MSCs in ARDS and sepsis are considered including preconditioning, altered gene expression, and alternative cell-free MSC-derived products, such as extracellular vesicles and conditioned medium.Expert opinion: MSC products present considerable therapeutic promise for ARDS and sepsis. Preclinical investigations report significant benefits and early phase clinical studies have not highlighted safety concerns. Optimization of MSC function in preclinical models of ARDS and sepsis has enhanced their beneficial effects. MSC-derived products, as cell-free alternatives, may provide further advantages in this field. These strategies present opportunity for the clinical development of MSCs and MSC-derived products with enhanced therapeutic efficacy.

Authors+Show Affiliations

School of Medicine Dentistry and Biomedical Science, Queen's University Belfast, UK.Division of Functional Genetics and Development, Roslin Institute, University of Edinburgh, Edinburgh, UK.School of Medicine Dentistry and Biomedical Science, Queen's University Belfast, UK.School of Medicine Dentistry and Biomedical Science, Queen's University Belfast, UK.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

33172313

Citation

Gorman, Ellen, et al. "Mesenchymal Stromal Cells for Acute Respiratory Distress Syndrome (ARDS), Sepsis, and COVID-19 Infection: Optimizing the Therapeutic Potential." Expert Review of Respiratory Medicine, vol. 15, no. 3, 2021, pp. 301-324.
Gorman E, Millar J, McAuley D, et al. Mesenchymal stromal cells for acute respiratory distress syndrome (ARDS), sepsis, and COVID-19 infection: optimizing the therapeutic potential. Expert Rev Respir Med. 2021;15(3):301-324.
Gorman, E., Millar, J., McAuley, D., & O'Kane, C. (2021). Mesenchymal stromal cells for acute respiratory distress syndrome (ARDS), sepsis, and COVID-19 infection: optimizing the therapeutic potential. Expert Review of Respiratory Medicine, 15(3), 301-324. https://doi.org/10.1080/17476348.2021.1848555
Gorman E, et al. Mesenchymal Stromal Cells for Acute Respiratory Distress Syndrome (ARDS), Sepsis, and COVID-19 Infection: Optimizing the Therapeutic Potential. Expert Rev Respir Med. 2021;15(3):301-324. PubMed PMID: 33172313.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Mesenchymal stromal cells for acute respiratory distress syndrome (ARDS), sepsis, and COVID-19 infection: optimizing the therapeutic potential. AU - Gorman,Ellen, AU - Millar,Jonathan, AU - McAuley,Danny, AU - O'Kane,Cecilia, Y1 - 2020/11/26/ PY - 2020/11/12/pubmed PY - 2021/3/16/medline PY - 2020/11/11/entrez KW - ARDS KW - ATMP KW - Acute Respiratory Distress Syndrome KW - COVID-19 KW - MSC KW - advanced Therapeutic Medicinal Product KW - mesenchymal stromal cell KW - sepsis KW - septic Shock SP - 301 EP - 324 JF - Expert review of respiratory medicine JO - Expert Rev Respir Med VL - 15 IS - 3 N2 - Introduction: Mesenchymal stromal (stem) cell (MSC) therapies are emerging as a promising therapeutic intervention in patients with Acute Respiratory Distress Syndrome (ARDS) and sepsis due to their reparative, immunomodulatory, and antimicrobial properties.Areas covered: This review provides an overview of Mesenchymal stromal cells (MSCs) and their mechanisms of effect in ARDS and sepsis. The preclinical and clinical evidence to support MSC therapy in ARDS and sepsis is discussed. The potential for MSC therapy in COVID-19 ARDS is discussed with insights from respiratory viral models and early clinical reports of MSC therapy in COVID-19. Strategies to optimize the therapeutic potential of MSCs in ARDS and sepsis are considered including preconditioning, altered gene expression, and alternative cell-free MSC-derived products, such as extracellular vesicles and conditioned medium.Expert opinion: MSC products present considerable therapeutic promise for ARDS and sepsis. Preclinical investigations report significant benefits and early phase clinical studies have not highlighted safety concerns. Optimization of MSC function in preclinical models of ARDS and sepsis has enhanced their beneficial effects. MSC-derived products, as cell-free alternatives, may provide further advantages in this field. These strategies present opportunity for the clinical development of MSCs and MSC-derived products with enhanced therapeutic efficacy. SN - 1747-6356 UR - https://www.unboundmedicine.com/medline/citation/33172313/Mesenchymal_stromal_cells_for_acute_respiratory_distress_syndrome__ARDS__sepsis_and_COVID_19_infection:_optimizing_the_therapeutic_potential_ L2 - https://www.tandfonline.com/doi/full/10.1080/17476348.2021.1848555 DB - PRIME DP - Unbound Medicine ER -